[Antibacterial treatment of urinary tract infections with co-tetroxazin (sterinor)].
In 100 patients with urinary tract infections the new benzyl-pyrimidine/sulphonamide combination Co-tetroxazin (Sterinor) was tested concerning its in vitro and in vivo action. In spite of the heterogenous cases (pyelonephritis 16%, obstructions 15%, prostatitis respectively urethritis 12% and cystitis 53%) and the relatively high average age (about 40% above the age of 60) a high therapeutic success was achieved. The clinical symptomatology improved up to 96% (respectively 83% without anymore pathological findings). This in vivo action correlated very well with the in vitro action in the agar diffusion test: fully sensitive 79%, moderately sensitive 15% and resistant only 6%. It is worth mentioning that the in vivo results with Sterinor were obtained with only 1/3 of the usual substance load (dosis) of the other benzylpyrimidine/sulphonamide combinations. This is due to the more favourable pharmacokinetic properties. Particularly in chronic patients, multi-morbidity and in elder patients this is clinically relevant. With this proven comparable clinical effect Co-tetroxazin is to be specified therefore to be more effective pharmacologically.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004338:Drug Combinations / Q000378:metabolism / Q000627:therapeutic use; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000378:metabolism / Q000627:therapeutic use*; D013411:Sulfadiazine / Q000378:metabolism / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology; D014556:Urine / Q000382:microbiology
D004338:Drug Combinations; D011743:Pyrimidines; D013411:Sulfadiazine; C026860:sulfadiazine, tetroxoprim drug combination
Antibakterielle Behandlung von Harnwegsinfektionen mit Co-tetroxazin (Sterinor).